Blog
Design of T cell circuits that sense antigen density to treat solid tumors The development of CAR T cells is one of the most important recent advances in the field of immunotherapies targeting cancer. This treatment is mainly used for patients suffering from leukemia or lymphoma. However, the application of…
mRNA-Based CAR T-Cell Therapy Descartes-11 Moves Into Phase 2 Trial in Myeloma Multiple myeloma is the second most common hematological malignancy in the world and remains difficult to treat despite numerous therapeutic advances and drug approvals. Patients continue to experience multiple relapses and complications of the disease, affecting many areas…
Promising Data From First-ever CRISPR Phage Therapy Trial Locus Biosciences announced that it has completed the world’s first clinical trial using a CRISPR-enhanced bacteriophage therapy in which CRISPR-Cas3 improved the natural ability of the virus to kill the E. coli bacteria behind urinary tract infections. The company decided to take…
CAR T-Cell Therapy Carves Out a Role in Multiple Myeloma Autologous and allogeneic CAR T cell therapies led by BCMA lead to profound and durable responses in heavily pre-treated multiple myeloma patients with a low incidence of severe cytokine release syndrome and neurotoxicity. According to Yi Lin, in the near…
Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection – Nature Communication A team of French researchers has come up with an anti-Covid solution which is an alternative to a vaccination and which could be ready for use in the form of a nasal spray. They have created a peptide, made up…
Universal CAR T cell therapy helps beat a hard-to-treat pediatric cancer Acute lymphoblastic leukemia (ALL) accounts for 25% of all pediatric cancer cases in the United States. There are several options for treating ALL in children aged 1-10 years, but infants under one year of age generally have a much…
Modified version of CAR T-cell therapy shows promise in targeting neuroblastoma The development of CAR T cells has facilitated the treatment of blood tumors. Moreover, this therapy is not effective against solid tumors such as neuroblastoma and has even revealed toxic effects that are due to the fact that most…
Penn study opens the door to let CAR T cells reach the tumor microenvironment The network of blood vessels in the tumour microenvironment remains one of the most difficult blockages for cell therapies to penetrate and treat solid tumours. However, a new study published in Nature Cancer explains that researchers at Penn Medicine found that combining CAR T cell therapy with a PAK4 inhibitor drug allowed modified cells to work their way through and attack the tumour, leading to significantly improved survival in mice. The genetic reprogramming of tumour endothelial cells lining the walls of blood vessels is caused by an enzyme known as PAK4. Penn’s team discovered that this enzyme reduces abnormal tumour vascularisation and improves T cell infiltration and CAR T cell immunotherapies in mouse models of glioblastoma. An experiment with T-RCA cell therapy led by EGFRvIII and a PAK4 inhibitor showed a nearly 80 percent reduction in tumour growth compared to mice that received CAR T cell therapy only five days after infusion. The targeting of PAK4 may therefore provide a unique opportunity to recondition the tumour microenvironment and improve T-cell–based cancer immunotherapy for solid tumours.
Potential treatment for glioblastoma multiforme TVI-Brain-1 immunotherapy, a potential treatment for glioblastoma multiforme, developed by TVAX Biomedical, has received Fast track designation by the U.S. Food and Drug Administration. Fast track is given to an experimental treatment for a disease that does not yet have one, or to a treatment…
The viral protein of SARS-COV-2 called SPIKE links through its binding domain to the ACE2 receptor located on many human cells. This allows the virus to enter the cells. Researchers then performed mutations on the SPIKE binding domain and most of them alter the expression of the binding domain and its binding to ACE2. This study therefore identified regions…
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.